Compare Quest Diagnostics Inc (DGX) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Wix.Com Ltd — how do they compare? Quest Diagnostics Inc trades at $204.98 (market cap $22.80B), while Wix.Com Ltd trades at $53.57 (market cap $2.21B). The key difference: Quest Diagnostics Inc is far larger — about 10.3× Wix.Com Ltd's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals.
| DGX | WIX | |
|---|---|---|
Market Cap | $22.80B | $2.21B |
Sector | Health | Technology |
52-Week High | $216.02 | $184.24 |
52-Week Low | $166.42 | $40.43 |
Enterprise Value | $28.82B | $1.77B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Wix trades at $52.41, up 4.53% today, with a bullish technical signal from moving averages but overbought RSI readings. Revenue grew to $1.99B in 2025, though net income fell to $50.65M, and the stock carries a high P/E of 62.84. Recent news highlights AI-related volatility and a partnership with Elavon to enhance small business payments.
The outlook is mixed: strong analyst consensus (67.5% buy ratings) and a $83.13 price target suggest upside, but risks include legal investigations, expense spikes, and negative shareholder equity. Earnings misses in Q1 2026 and high valuation metrics warrant caution despite growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
